Aliases:This biomarker is also known as:
- pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
- Heparin-binding neurite outgrowth-promoting factor 1,
- Heparin-binding growth factor 8,
- Heparin-binding brain mitogen,
- heparin-binding brain mitogen,
- Osteoblast-specific factor 1,
- heparin-binding growth-associated molecule,
- Heparin-binding growth-associated molecule,
- osteoblast-specific factor 1,
- heparin-binding neurite outgrowth-promoting factor 1,
- heparin binding growth factor 8,
- neurite growth-promoting factor 1,
- heparin affin regulatory protein,
- heparin-binding growth factor 8,
Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.
PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.